Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data (Q33516685)

27 July 2017

Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data (English)

1 reference

27 July 2017

0 references

1 reference

Rajitkanok Amy Puenpatom

series ordinal

1

1 reference

PubMed ID

19940413

27 July 2017

Timothy W Victor

series ordinal

2

1 reference

PubMed ID

19940413

27 July 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

27 July 2017

Postgraduate Medicine

1 reference

27 July 2017

121

1 reference

27 July 2017

9-20

1 reference

27 July 2017

6

1 reference

Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study

27 July 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Metabolic syndrome in rheumatological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

The metabolic syndrome and cardiovascular disease: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Osteoarthritis and nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Cyclooxygenase-2 and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Obesity and osteoarthritis: more complex than predicted!

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Epidemiology of osteoarthritis: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Metabolic syndrome: a multiplex cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

The underlying mechanisms for development of hypertension in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

COX-2 inhibitors and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Selective COX-2 inhibitors and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Update of ACR guidelines for osteoarthritis: role of the coxibs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Topical therapy for osteoarthritis: clinical and pharmacologic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Primary care provider concerns about management of chronic pain in community clinic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

The truth about pain management: the difference between a pain patient and an addicted patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Abuse liability in opioid therapy for pain treatment in patients with an addiction history

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Opioids and cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2073

RETRACTED: Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1097/00000539-199906000-00016

Identifiers

DOI

10.3810/PGM.2009.11.2073

1 reference

27 July 2017

1 reference

PubMed ID

19940413